Primary Signet Ring Cell Carcinoma of the Lung with Cerebellar Metastasis Showing Full Response to Cisplatin and Docetaxel Therapy

Abstract

Introduction. Primary signet ring cell carcinoma (SRCC) of the lung is a very rare disease. We describe a new case of primary SRCC of the lung with cerebellar metastasis, which responded well to the therapeutic approach with cisplatin and docetaxel. Case Report. A 41-year-old female patient (nonsmoker) was consulted to our oncology outpatient clinic after cerebellar metastasectomy. The histopathological diagnosis was SRCC metastasis. The primary tumor was unknown. The PET-CT imaging showed a hypermetabolic mass in the right middle lobe of the lung and hypermetabolic mediastinal lymph node stations. Oesophagogastroduodenoscopy and colonoscopy showed no evidence of gastrointestinal system tumor. The clinical diagnosis of primary SRCC of the lung was made and the administration of six rounds of cisplatin and docetaxel treatment was planned. After the chemotherapy the PET-CT scan to evaluate the therapy response showed full metabolic regression of the primary tumor and the mediastinal lymph nodes. There was no evidence of new metastasis. Conclusion. Primary SRCC of the lung is a very rare disease with poor prognosis. There are not many cases in literature and no standardized chemotherapy protocols. Cisplatin and docetaxel may be a good treatment option.

Life Threatening haemoptysis in primary lung cancer-signet ring cell carcinoma

“…Our patient failed to show any such driver mutation on next generation sequencing. In oncologic literature chemotherapeutic agents such as platinum based (cisplatin) and microtubule assembly destabilizer (docetaxel) also have been used with benefit to some extent however the prognosis of primary lung SRCC remains poor [ 12 ].…”

Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy

“…Primary SRCC of the lung is a very rare disease, originally described by Kish et al in 1989 [8]. The incidence varies from 0.14% to 1.9% of all lung cancers [9]. Tsuta et al reported on 2640 surgically resected primary lung carcinomas; 39 (1.5%) of these tumors showed SRCC components.…”

“…Whereas most lung cancers are adenocarcinomas, primary signet ring cell (adeno)carcinoma (SRCC) of the lung represents a rare uncommon condition, originally described by Kish et al in 1989 [8]. The incidence varies from 0.14% to 1.9% of all lung cancers [9].…”

Primary Lung Signet Ring Cell Carcinoma Presenting as a Cavitary Pancoast Tumor in a 32-Year-Old Man

“…The presence of these rearrangements has therapeutic significance, as tumors with ROS1 rearrangements and the EML4-ALK translocation have been shown to respond to the smallmolecule ALK inhibitor, crizotinib. [8][9][10] Here we report a case of primary lung SRCC presenting as a cavitary Pancoast tumor in a 32-year-old male smoker. Beyond the rarity of primary lung SRCC itself, we discuss several features of the case that make it noteworthy.…”

“…The immunohistochemical staining profile for primary lung SRCC typically features positivity for TTF-1, CK7, and napsin A, with negativity for CK20 and CDX-2. 9,10 Primary lung SRCC has recently been associated with rearrangements of the ALK and ROS1 genes. A 2014 study by Boland et al 9 found ALK rearrangements in 14 of 53 SRCC cases (26%) and ROS1 rearrangements in 3 of 47 SRCC cases (6%).…”